In vitro metabolism of pregnenolone (P 5 ) as well as production of 17b-estradiol (E 2 ) were studied in uteri of untreated and luteinizing hormone (LH)-treated mice that had been ovariectomized (OVX) at late-diestrus stage. In the uteri of untreated mice, [ 3 H]pregnenolone was shown to be metabolized to D 5 -components such as 17a-hydroxypregnenolone (17a-P 5 ) and dehydroepiandrosterone (DHEA), whereas LH treatment resulted in significant increases in the formation of progesterone (P 4 ), 17ahydroxyprogesterone (17a-P 4 ), androstenedione (AD) and testosterone (T). This was assessed by thinlayer chromatography (TLC) and high-performance liquid chromatography (HPLC). The content and release of P 4 was shown to be stimulated by LH. Trilostane, an inhibitor of 3b-hydroxysteroid dehydrogenase (3b-HSD), inhibited LH-induced P 4 synthesis and its release in a dose-dependent manner. A considerable increase in [ 3 H]estradiol formation from [ 3 H]testosterone was recorded in LHstimulated uterine tissue as compared with the control, indicating the stimulatory effect of LH on aromatase activity. LH-stimulation in the synthesis of P 4 and E 2 in OVX mouse uteri was mimicked by dbcAMP (cell-permeable cAMP). Incubation with LH was shown to augment the conversion of P 4 to various D 4 -3-oxosteroids. In vitro effects of LH on the synthesis and metabolism of P 4 , as well as on the stimulation of aromatase activity, were more pronounced in the uterine tissue of LH-primed OVX mice. Thus the results of the present study indicate that, under specific conditions, the uterus of the mouse behaves like steroidogenic tissue. Its prompt response to LH reveals the probable physiological relevance of the existence of LH receptors of high binding affinity in the uterine tissue of the mouse, as reported earlier.
Introduction
Contrary to the conventional belief that luteinizing hormone (LH) and human chorionic gonadotropin (hCG) regulate only gonadal functions, several recent studies have shown that LH/hCG receptors are also present in a variety of non-gonadal tissues (1±6). Of these, the studies on the uteri of both primates and non-primates have been the most extensive. The presence of high-affinity and low-capacity binding sites for LH and hCG has been reported for the uterine tissue of pigs, rats, mice and rabbits (7±10), as well as for human endometrium and myometrium (1, 2, 11) . The concentrations of uterine receptors fluctuate with the stages of reproduction. The amounts of receptors in porcine uterine tissue are higher during the luteal phase and in early pregnancy than in follicular phase of the estrous cycle (1, 12, 13) . In the mouse uterus, the amounts are high during the late-diestrous stage (9) , whereas in rat uterus, this occurs during the metestrous stage (14) . The functional relevance of the existence of LH/hCG receptors in the mammalian uterus is not clear, although some of the earlier studies reported regulation of increased production of progesterone (P 4 ) by the induction of LH (14) . We have also shown augmented conversion of cholesterol to pregnenolone (P 5 ) in OVX mouse uteri following the induction of LH (9) . This has led us to investigate whether the mouse uterus, like the ovary, is really capable of synthesizing P 4 and 17b-estradiol (E 2 ) in response to LH stimulation through modulation of the activity of D 5 -3b-hydroxysteroid dehydrogenase (D 5 -3b-HSD) and aromatase.
Materials and methods

Animals
For at least 15 days prior to use, two-to three-monthold, albino, female virgin mice (25±30 g) of an inbred strain were kept on a schedule of 12 h light:12 h darkness and were allowed to take food and water ad libitum. Vaginal smears were examined daily for two consecutive 4 day estrous cycles; only the normally cycling mice were used.
Chemicals
Ovine luteinizing hormone (oLH) was obtained as a gift from Dr A F Parlow, NIDDK (Lot. No. oLH-26, AFP 5551B). D 5 [4, H]pregnenolone (sp. activity 11000 mCi/mmol), [1, 2, 6, H]progesterone (sp. activity 6800 mCi/mmol), [2, 4, 6, H]estradiol-17b (sp. activity 22,500 mCi/mmol) and [1, 2, 6, H]testosterone (sp. activity 5400 mCi/mmol) were purchased from Amersham International UK. The purity of these radiochemicals was checked by thin-layer chromatography (TLC) in a benzene/acetone (4:1, v/v) solvent system. Minimum essential medium (MEM), bovine serum albumin (BSA) and all authentic steroids were purchased from Sigma Chemical Company (St Louis, MO, USA). Highly purified P 4 and E 2 antisera were donated by Professor Gordon Niswender (Colorado State University, Fort Collins, USA). The crossreactivities of various steroids with P 4 and E 2 antibodies were checked before their use in radioimmunoassay (RIA). Acetonitrile and methanol (Spectrochem, India) were of HPLC grade.
Tissue preparation
Female mice at diestrus stage II were ovariectomized and after 7 days they were separated into two groups. One group was primed with three i.m. injections of LH (500 ng/mouse) on alternate days, whereas those of the other group (control), which comprised twice the number of mice, received saline injections. On day 7, uteri from the mice in both groups were removed and washed with pre-chilled MEM gassed with 95% O 2 /5% CO 2 . Equal amounts of tissues (50 mg) from the control and LH-primed groups were placed in 5 ml sterile glass beakers each containing 1.0 ml MEM; these were then incubated for 4 h at 37^1 8C to study the steroid metabolism, to determine 3b-HSD activity, to estimate P 4 and E 2 content, and to assay aromatase activity.
In vitro incubation of uterine tissue
Uterine tissues (50 mg) from saline-injected OVX mice were incubated with or without LH (500 ng/ml) in the presence of [ 3 H]P 5 2 Â 10 6 c.p.m., 138 pmol) and NAD (300 mM) or [ 3 H] P 4 2 Â 10 6 c.p.m., 222 pmol) and NADPH (5 mmol) in 1.0 ml MEM (pH 7.4) with constant shaking for 4 h. LH-primed mouse uterine tissues were also incubated similarly with LH. Incubations were terminated after placing of the beakers on ice. For P 5 metabolism, the following unlabeled steroids (15 mg each) were added to the medium as carrier steroids at the completion of incubation: P 5 , 17a-P 5 , dehydroepiandrosterone (DHEA), P 4 , 17a-P 4 , androstenedione (AD), testosterone (T) and E 2 . For P 4 metabolism, 17a-P 4 , P 4 , T, E 2 , AD, 3a-hydroxy-5bpregnan-20-one (3a-OH-5b-pregnan-20-one) and 5b-pregnan-3a,17a,20b-triol (5b-3a,17a,20b-P) were used.
Pregnenolone metabolites obtained from uterinetissue incubations in response to LH were also fractionated by HPLC. For this purpose, uterine tissues from both saline-injected and LH-primed OVX mice were incubated without or with LH (500 ng/incubation) in the presence of unlabeled P 5 (15 mg/ml) in 1.0 ml MEM for 4 h.
For measurement of D 5 -3b-HSD coupled with D 5 2D 4 isomerase (D 5 -3b-HSD) activity, the procedure described by Imataka et al. (15) was used. In brief, uterine tissues (50 mg) were incubated with [ 3 H]P 5 and NAD without or with LH (500 ng/ml) for 4 h with constant shaking. Incubation was terminated by placing the beakers on ice. No unlabeled steroids were added as carriers.
To determine the P 4 and E 2 contents, uterine tissues, after being minced, were incubated without or with LH (500 ng/ml) for 4 h. Upon termination of incubation, tissues and media were collected separately. Steroids were extracted by the addition of 4 ml diethylether. The amounts of P 4 and E 2 were estimated by RIA according to the previous procedure (9) based on the description of Korenman et al. (16) .
Aromatase activity of the uterine tissue in response to LH was determined by using the method of Chan & Tan (17) . Uterine tissues (50 mg) were incubated in the absence or presence of LH (500 ng/ml) for 6 h at 37^1 8CX All incubations contained 280 pmol [ 3 H]T 2 Â 10 6 c.p.m., sp. activity 5400 mCi/mmol).
Extraction, identification and quantification of steroids
Upon termination of incubation either with unlabeled or labeled P 5 or with labeled P 4 or T, tissues were harvested by centrifugation at 3000 g and homogenized in phosphate buffer (pH 7.4). Steroids were extracted with dichloromethane (DCM) 5 ml Â 3 and evaporated to dryness. Dried materials were dissolved in methanol and subjected to TLC on silica gel G-coated plates (0.25 mm thickness). To obtain P 4 and P 5 metabolites, plates were developed in the solvent systems containing chloroform/diethyl ether (9:1, v/v) and benzene/acetone (4:1, v/v) respectively. For HPLC analysis, steroids were extracted with diethylether 4 ml Â 3 and evaporated to dryness. Dried materials were dissolved in methanol and subjected to HPLC. To determine aromatase activity, plates were developed in the solvent systems benzene/acetone (4:1, v/v) and diisopropyl ether/petroleum spirit/acetic acid (70:30:1, v/v). Each radioactive spot was identified by (a) comparing its mobility on a thin-layer chromatogram with that of the corresponding authentic preparation, (b) by comparing the chemical behaviour of respective radioactive metabolites with that of authentic steroids in acetylation (18) and oxidation by 0.5% CrO 3 in 90% aqueous acetic acid solution (19) , and (c) by determining the constant specific activity of crystals after repeated crystallization of radioactive metabolites with the authentic steroid preparation (20) ( Table 1) . Identified materials were recovered from the silica gel by extraction with chloroform/methanol (1:1, v/v), and the radioactivity in each aliquot was estimated in 3 ml of a toluene-based PPO-POPOP system in a liquid scintillation counter (LS 6000 S.C.; Beckman). Values were presented as per cent conversion of [ 3 H]P 5 or 
High-performance liquid chromatography
HPLC was performed using a Model 501 pump, a UV detector, (Model 486), a Model 410 differential refractometer and a Model 740 data module (all from Waters Associates, Inc., Milliford, MA, USA). The column used was a C 18 m Bondapak stainless steel reverse-phase column 3X9 mm iXdX Â 30 cm; Waters Associates, Inc.). The mobile phase used was acetonitrile/water (40:60, v/v) at a constant flow rate of 1 ml/ min. The absorbance of the effluent was measured at 254 nm and the column was flushed with HPLC-grade 100% methanol for 10 min before the injection of samples. Initially, the retention times of eight authentic standard steroids were recorded ( Table 2 ) and then a chromatogram was obtained using a mixture of those eight steroid standards. The samples were injected separately and the peak and retention time for each steroid metabolite were recorded and compared with those of corresponding authentic steroid peaks. was added separately to 3 ml of toluene-based scintillation fluid containing PPO and POPOP and then counted in a liquid scintillation counter. The sensitivity of the RIA for P 4 was 16 pg/ mg uterine tissue protein or 12 pg/ml medium; for E 2 , the sensitivity was 10 pg/mg uterine tissue protein or 6 pg/ml medium. The intra-assay coefficients of variation for P 4 and E 2 were 7% and 6% and the interassay coefficients of variation were 9% and 8% respectively. Results were expressed as pg steroid content/mg uterine tissue protein and pg steroid released/ml medium.
Steroid
Statistical calculations
Data were analyzed by one-way ANOVA followed by Scheffe's simultaneous confidence test (22) . All values * Specific activities of the residues before crystallization.
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were expressed as the mean^S.E.M. A probability level of P , 0X01 was considered as significant.
Results
When saline-injected OVX mouse uterine tissue was incubated with [ 3 H]P 5 without any hormonal stimulation, 10 metabolites were obtained by TLC (Table 3) . Of these, six were identified and four remained unidentified. Of the identified metabolites, 17a-P 5 and DHEA were found to be the major ones ( Table 3 ). Conversion of P 5 to 17a-P 5 was 6.4% and to DHEA was 6.05%. The formation of P 4 was conspicuously less (0.25%), indicating that the D 5 -pathway was dominated in unstimulated OVX mouse uterine tissue. The production of 17a-P 4, AD and T was negligible. There was also less formation of unidentified metabolites, of which two were polar and two non-polar components. In contrast, when uterine tissue of saline-injected OVX mice was incubated in the presence of LH, P 4 was found to be the major metabolite. Tritiated P 5 recovery in such tissues was approximately 21% of the total radioactivity added; 9.5% of the radioactivity was co-migrated as P 4 , 3.1% as 17a-P 4 , 4.8% as T, and 6.5% as AD. The formation of 17a-P 5 and DHEA was found to be significantly P , 0X01 low compared with the OVX. The levels of unidentified metabolites remained almost unaltered. Interestingly, the rate of conversion of P 5 to D 4 steroid metabolites was significantly higher when OVX mice were initially primed with LH for three doses and uterine tissues were further incubated with LH. In these cases, conversion to P 4 and 17a-P 4 was found to be 19.5% and 6.63% respectively of total radioactivity. Metabolites of P 5 identified by TLC were confirmed after HPLC fractionation. The retention times ( Table 2) and peaks of individual standard steroids in HPLC were marked as references. In the chromatogram for the saline-injected OVX samples, only three peaks of absorbance were coincident with the retention times and peaks for authentic DHEA, 17a-P 5 and P 5 respectively (Fig. 1A ). In addition, there were three unidentified small peaks. In the chromatogram for OVX LH samples, six peaks were obtained; the retention times and peaks of four of these were found to coincide with those of T, 17a-P 4 , P 5 and P 4 (Fig. 1B) . Comparison of the absorbances of the peaks revealed the existence of greater amounts of P 4 than of any other metabolite in OVX LH samples. Interestingly, in uterine tissue samples of LH-primed mice incubated with LH, nine peaks were obtained; of these, five were shown to coincide with peaks for T, 17a-P 4 , P 5, AD and P 4 respectively (Fig. 1C ) and the remaining four were unidentified. Peaks identified as AD and P 4 were shown to be greater than any other peaks in the chromatogram. It is noteworthy that a peak for DHEA was not observed in LH-stimulated samples ( Fig. 1B and C) .
For measurement of D 5 -3b-HSD activity, uterine tissue was incubated with [ 3 H]P 5 in the presence of NAD for 4 h. The rate of formation of P 4 was significantly high P , 0X01 in the uterine tissue of OVX mice incubated with LH in vitro, and, when LHprimed tissues were incubated in the presence of LH, the production of P 4 was more pronounced (Fig. 2) . From the radioactivity of P 4 , the calculated activity of D 5 -3b-HSD was 0.63 pmol/mg protein for OVX, 6.5 pmol/mg protein for OVX LH and 10.7 pmol/ mg protein for LH-primed OVX LH mouse uterine tissue.
The addition of LH during the incubation of uterine tissue from saline-injected OVX mice greatly augmented P , 0X01 the tissue content (synthesis) of P 4 as well as its release (content in the medium) in comparison with the OVX control (Table 4 ). Both the synthesis and the release of P 4 were found to be more pronounced P , 0X01 when LH-primed uterine tissues were incubated in the presence of LH in the medium (Table 4 ). Trilostane, an inhibitor of 3b-HSD, was shown to inhibit LH-induced P 4 synthesis and release (almost in a dose-dependent manner) in LHprimed OVX mouse uterine tissue (Fig. 3) . LHstimulated P 4 synthesis and release were found to be mimicked by dbcAMP. At a dose of 0.1 mM, dbcAMP significantly P , 0X01 stimulated the synthesis and release of P 4 in saline-injected OVX mouse uterine tissue relative to the control (Fig. 4) .
In the uteri of saline-injected OVX mice, the tissue content of E 2 and its release in the medium were very low. The addition of LH was shown to augment P , 0X01 both the synthesis and the release of E 2. A further increase was observed in the tissue from LHprimed mice incubated with LH in the medium ( Table 5 ). Both of these processes were shown to be mimicked by dbcAMP (Fig. 5) . A higher dose of dbcAMP was found to be more effective.
When uterine tissue from saline-injected OVX mice (Fig. 6 ). Furthermore, the formation of [ 3 H]E 2 was significantly higher when LH-primed OVX mouse uterine tissue was incubated with LH. These findings indicate that LH stimulates aromatase activity (Fig. 6 ). Saline-injected OVX mouse uterine tissue was found to convert [ 3 H]P 4 to several metabolites (listed in Table 6 ). The D 4 -3-oxosteroid metabolites obtained from P 4 comprised 17a-P 4, T and AD. Small amounts of 3a-OH-5b-pregnan-20-one, 5b-3a,17a,20b-P and E 2 were also found ( Table 6 ). In vitro LH stimulation of such tissue significantly increased the production of all of the D 4 -3-oxosteroids and E 2 , but failed to alter the concentrations of 3a-OH-5b-pregnan-20-one and 5b-3a,17a,20b-P. When LH-primed uterine tissue was incubated in the presence of LH, no significant increase in the formation of metabolites was observed ( Table 6 ).
Discussion
In the present study, there is a clear evidence that uterine tissue of the mouse is capable of synthesizing P 4 from the precursor P 5. Progesterone (P 4 ) is subse-quently metabolized to C 19 steroids, particularly the 17-oxo ones, which, in turn, lead to final conversion to E 2 . The study of D 5 -3b-HSD activity in vitro substantiates the D 4 -pathway of P 5 metabolism. The most significant findings are the stimulatory role of LH in in vitro synthesis and metabolism of P 4 as well as the activation of aromatase in mouse uterine tissue.
In OVX mouse uterine tissue under basal conditions, i.e. without LH stimulation, P 5 was metabolized primarily to 17a-P 5 and DHEA via the D 5 -pathway. When such tissues were incubated in the presence of LH, or when LH-primed OVX uterine tissues were incubated further with LH, the D 5 -pathway was replaced by the D 4 -pathway, resulting in the formation of P 4 along with other D 4 metabolites. This was observed using TLC and was further substantiated by HPLC. The increased activity of D 5 -3b-HSD when stimulated by LH, using P 5 as the substrate, also lends support to the view that there is a shift from the D 5 -to the D 4 -pathway in mouse uterine tissue. The findings that trilostane, an inhibitor of D 5 -3b-HSD, effectively blocked P 4 synthesis and release from P 5 in uterine tissue agrees with a previous report on gonads, in which LH/hCG was shown to exert a steroidogenic influence through modulation of D 5 -3b-HSD (23) .
From the present study, as well as from some earlier reports (8, 9, 11) , it is clear that the mechanism by which LH exerts its stimulatory effect in the mouse uterus involves its initial binding with an LH-specific receptor in the uterine cell membrane and the activation of adenylate cyclase activity to produce cAMP which, in turn, stimulates the synthesis of P 4 . The high rate of conversion of cholesterol to P 5 in LHstimulated OVX mouse uterine tissue, reported previously by us (9) , not only indicates the earlier action of LH on uterine mitochondrial steroidogenesis but also justifies the availability of P 5 within the cells of this organ for subsequent conversion to C 19 steroids. The present study furnishes ample evidence that dbcAMP mimics the action of LH for both synthesis and release of P 4 by the OVX mouse uterus. This finding corroborates the earlier observations, in which hCG was reported to stimulate P 4 synthesis in metestrus rat uterus via a cAMP-dependent pathway (10) .
Another aspect of LH action was the significant augmentation of aromatase activity in the OVX mouse uterus. This is supported by a high rate of metabolism of aromatizable androgen (T to E 2 ) and by enhanced synthesis and release of E 2 under LH stimulation. That the mammalian uterus possesses several steroidogenic enzymes participating in the conversion of steroid precursors to metabolites has been documented (10, 24±27), but it is not clear how the activities of such enzymes are regulated. The increased conversion of labeled T to labeled E 2 found in the present study and also that which occurs in the stromal cells of human endometrium, reported recently (28) , amply indicate that another locus of LH action in the uterine steroidogenic cascade is the regulation of aromatase activity in addition to that of cytochrome P-450scc (9) and D 5 -3b-HSD activities. Progesterone metabolism by the mouse uterus is not unexpected, since there are several earlier reports showing that mammalian endometrial tissue can metabolize P 4 (25, 26, 29±31) . The influence of the E 2 metabolism of P 4 by this tissue is primarily directed towards the formation of some inactive metabolites (24) . In the present study, very small amounts of inactive metabolites of P 4 , namely 3a-OH-5b-pregnan-20-one and 5b-3a-17a,20b-P, have been identified in both LH-stimulated and -unstimulated uterine tissues. Such small amounts may be due to the absence of endogenous E 2 in the OVX mouse. What is interesting, here, is that, under LH stimulation, P 4 metabolism in the uterine tissue of OVX mice is channeled towards the steroid-synthesizing pathway, with the formation of aromatizable androgen through 17a-P 4 and AD.
Finally, it can be concluded that mouse uterus participates in the synthesis and metabolism of P 4 in the same way as the mammalian ovary, and that it is a potential organ for the synthesis of E 2 through aromatase. It is significant that, as in mammalian ovary, LH exerts its stimulatory influence in these processes. It remains to be determined whether there is any role for follicle-stimulating hormone in uterine steroidogenesis. 
